Digestive Health Newsletter

How to Stay Fit When You Have Inflammatory Bowel Disease

Alan V. Safdi, MD, FACG

Volume 24, 
January 01, 2011

by Alan V. Safdi, MD, FACG

Alan Safdi Alan V. Safdi, MD, FACG, is the President of the Ohio Gastroenterology and Liver Institute, Past Chairman Crohn's and Colitis Medical Advisory Committee, Cincinnati, and the President of the Consultants for Clinical Research. He is also the chairman of Gastroenterology at Deaconess Hospital, where he has served on the hospital’s Executive Committee. Dr. Safdi has also served as the President, Treasurer, and Secretary for the Southwest Ohio Digestive Disease Society. His group has published a number of articles in the American Journal of Medicine, the American Journal of Gastroenterology, the Annals of Internal Medicine, and a variety of other prominent medical journals.



Table of Contents



Introduction

Exercise is good for almost everyone, but it can be a challenge to stay fit when you have a chronic illness like Inflammatory Bowel Disease (IBD). This newsletter reviews the benefits of physical activity and includes tips about how to work with your disease instead of against it. If you have not yet made a New Year’s resolution, it’s not too late to make physical fitness your goal for 2011. For inspiration, read about Carrie Johnson, an Olympic kayaker who doesn’t let Crohn’s disease get in her way.

Back to Top

Can physical activity really make a difference with my Inflammatory Bowel Disease?

Physical activity can decrease tension and stress, increase circulation and energy, induce feelings of well being, and aid digestion and body weight maintenance. What’s more, a recent review of seven studies suggests that, for people with IBD, physical activity is associated with a general decrease in disease activity. In several of the studies, the physical activity was as simple as low-intensity walking (for example, 30 minutes, three times a week).

Back to Top

What if I don’t like to exercise?

Don’t think of it as “exercise,” think of it as being active, and then find an activity you like to do. You are more likely to make it a permanent part of your routine if you enjoy what you’re doing. Try walking, biking, dancing, or anything that gets you moving. Start slowly and remember that any amount of physical activity is better than none.

Back to Top

What about when I’m having a flare?

During a flare, your body is working hard to fight IBD symptoms; pushing yourself will only make that job more difficult. Take it easy by trying gentle exercise like yoga and tai chi, and save more rigorous physical activity for between flares. Remember that you can decrease your risk of relapse by continuing to take your medication, even when you are feeling well.

Back to Top

Curbing my fluid intake seems to help with diarrhea. Is that ok to do when I exercise?

It’s important to keep hydrated while exercising, so be sure to listen to your body and drink when you’re thirsty. A good rule of thumb is to drink 8 to 10 ounces just before exercising, and 4 to 6 ounces every 10 to 20 minutes during exercise. This will decrease your risk of dehydration, especially during a flare. Try electrolyte-based drinks, which can help you maintain a balance between dehydration and diarrhea. Since many sport drinks contain a lot of sugar, you may want to dilute them with water. Finally, remember that coffee, tea, and cola do not help as much with hydration, since they act as very mild diuretics.

Back to Top

Is it my imagination, or is there something about my aerobics class that sends me running to the bathroom?

Some types of physical activity, like aerobics or running, can be hard on the digestive tract, due to repeated bouncing and decreased blood flow to your intestines. To get fit without battling bathroom breaks, try lower-impact activities that involve smoother motions, like skating, cycling, or cross-country skiing. If you have access to a pool, you also might find that exercising in water is a comfortable option.

Back to Top

Is it ok to exercise if I’m taking immunosuppressive drugs?

Taking immunosuppressive drugs can make you more susceptible to other illnesses, so be careful to limit your exposure to germs. If you exercise at a gym, use hand wipes to clean shared equipment and remember to wash your hands immediately following your workout.

Back to Top

I know that Inflammatory Bowel Disease increases my risk for osteoporosis. Can exercise help keep my bones strong?

Yes! Bone is living tissue that gets stronger with weight bearing exercise, like walking, dancing, and weight or resistance training. Strengthening your bones helps reduce your osteoporosis risk. Although there are currently no precise guidelines, even simple things can help, like walking more often and using the stairs instead of the elevator, or activities like gardening and housework. Also remember to get your vitamin D level checked.

Back to Top

I know that Inflammatory Bowel Disease increases my risk for colon cancer. Can exercise help counter this?

Yes! A recent review of studies found that exercise can lower colon cancer risk by almost 25%. For example, one study found that the equivalent of walking briskly for 5 to 6 hours a week decreased colon cancer risk by 23%, when compared to walking only one-half hour a week. Researchers hypothesize that exercise decreases intestinal inflammation and has a positive effect on immune function. This is great news for everyone and especially for people with IBD, given their increased colon cancer risk.

Back to Top

Conclusion

Regardless of the physical activity you choose, always check in with your physician before trying anything new. Then, once you get started, be sure to keep your doctor in the loop, especially if you notice any change in your IBD symptoms.

Back to Top

Olympic Kayaker Carrie Johnson Talks about Exercise and Crohn’s Disease

Carrie Johnson

According to Olympic kayaker Carrie Johnson, the two most challenging aspects of her sport are balance and strength. She clearly has ample strength and balance, both on the water and off. Diagnosed with Crohn’s disease in 2003 at age 19, she went on to win the Kayaking World Cup in 2007 and placed fifth in the world championships. She was the first U.S. kayaker to qualify for the 2008 Olympic Games and the only female U.S. kayaker to compete in the 1,500-meter race. At the 2004 Olympic Games in Athens, she finished tenth, the highest ever for a U.S. kayaker.

Johnson, now 25, gets her strength from a rigorous training regimen that includes paddling every morning and most afternoons, road biking, swimming and lifting weights. The balance she gets from listening to her body and making adjustments when necessary. She also knows that with a training regimen like hers, she must rest regularly in order to prevent flare-ups.

“For me, road biking is a good substitute for running,” explains Johnson. “There is less up-and-down movement. I used to run, but when I run I have to go to the bathroom frequently, which for a Crohn’s patient can be a very immediate thing.”

Johnson felt tired and weak and lost 20 pounds in just over a month before she was diagnosed in 2003. Then she had a flare-up again in 2008-2009 that prevented her from training and competing. “I spent a lot of time inside sitting on the couch during those periods,” she says, “because I couldn’t do anything else physically, which is one of the most frustrating things about this illness.”

She thrives on being active and says she feels better emotionally and physically when she exercises. “Exercise is a big stress reducer for me. And from a Crohn’s perspective, having a routine where I’m active makes me feel more regular,” she says. “It keeps things moving. But everyone is different.”

Johnson stresses that it’s important for everyone to discover what’s best for their body. “Worry about going to the bathroom can be very intimidating, and it was something I worried about a lot when I was first diagnosed.” She recommends making changes that reduce that kind of worry and stress, such as running on a treadmill with a bathroom nearby, for instance, instead of running outdoors. “It’s a good idea to test something out in a safe place to see how the activity affects you,” she says.

Johnson has also found that it’s helpful to think about and explore the options you have, instead of focusing only on the obstacles. “It’s important not to become too frustrated with the things you can’t do as well because of Crohn’s,” she says. “It helps me to think in broader terms and to remind myself that we all have things we can or can’t do, whether or not we have this disease.”

Johnson’s immediate goal is qualifying to race in the U.S. World Championships in August and then qualifying for the London Olympics. After that she hopes to study veterinary medicine, for which she is now taking prerequisite courses.

“I see myself competing until 2012, and then I’ll just have to take it one day at a time,” she says. Which sounds exactly like the helpful advice she has given herself and heeded every day since she was diagnosed seven years ago.

Back to Top

Important Safety Information about AZASAN

WARNING: Chronic immunosuppression with this purine antimetabolite increases risk of neoplasia in humans. Physicians using this drug should be very familiar with this risk as well as with the mutagenic potential to both men and women and with possible hematologic toxicities. See WARNINGS section in complete Prescribing Information.

AZASAN® (azathioprine tablets) 75/100 mg is indicated as an adjunct for the prevention of rejection in renal homotransplantations, and also for the management of active rheumatoid arthritis to reduce signs and symptoms.The most commonly reported side effects associated with AZASAN therapy are leukopenia and/or thrombocytopenia, secondary infections, neoplasia, nausea, vomiting, diarrhea, fever, myalgias, skin rashes, and hepatotoxicity. AZASAN therapy should be given cautiously when used concomitantly with allopurinol, ACE inhibitors, and other agents affecting myelopoiesis. AZASAN is contraindicated in pregnant and lactating women and in patients who have shown hypersensitivity to this product.

Consult with your physician to see if this product is right for you.

Complete Prescribing Information for AZASAN, including BOXED WARNINGpdf

Important Safety Information about METOZOLV® ODT

WARNING: TARDIVE DYSKINESIA

See full prescribing information for complete boxed warning.

Treatment with metoclopramide can cause tardive dyskinesia, a serious movement disorder that is often irreversible. The risk of developing tardive dyskinesia increases with the duration of treatment and the total cumulative dose.

Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia. There is no known treatment for tardive dyskinesia. In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.

Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.

METOZOLV® ODT (metoclopramide HCl) is indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux disease (GERD) who fail to respond to conventional therapy and for the relief of symptoms associated with acute and recurrent diabetic gastroparesis (diabetic gastric stasis) in adults. Therapy should not exceed 12 weeks in duration. Take on an empty stomach up to four times daily, at least 30 minutes before eating and at bedtime.

METOZOLV ODT is contraindicated in patients with intestinal obstruction, hemorrhage, or perforation; pheochromocytoma; known sensitivity or intolerance to metoclopramide; epilepsy; or are receiving concomitant medications with extrapyramidal reactions.

Extrapyramidal symptoms (EPS), manifested primarily as acute dystonic reactions, occur in approximately 1 in 500 patients treated with the usual adult dosages of 30 to 40 mg/day of metoclopramide. These usually are seen during the first 24 to 48 hours of treatment with metoclopramide, occur more frequently in pediatric patients and adult patients less than 30 years of age and are even more frequent at higher doses.

Drug-induced Parkinsonism can occur during metoclopramide therapy, more commonly within the first 6 months after beginning treatment, but also after longer periods. Patients with a history of Parkinson’s disease should be given metoclopramide cautiously, if at all, since such patients can experience exacerbation of Parkinsonian symptoms when taking metoclopramide.

There have been rare reports of an uncommon but potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) associated with metoclopramide. Clinical manifestations of NMS include hyperthermia, muscle rigidity, altered consciousness, and evidence of autonomic instability. The management of NMS should include immediate discontinuation of metoclopramide and other drugs not essential to concurrent therapy.

Depression associated with metoclopramide use has occurred in patients with and without a history of depression. For those patients with a prior history of depression, metoclopramide should only be given if the expected benefits outweigh the potential risks.

In one study in hypertensive patients, intravenously administered metoclopramide was shown to release catecholamines; hence, caution should be exercised when metoclopramide is used in patients with hypertension. Any rapid rise in blood pressure associated with METOZOLV ODT use should result in immediate cessation of metoclopramide use in those patients.

Since metoclopramide produces a transient increase in plasma aldosterone, patients with cirrhosis or congestive heart failure may be at risk of developing fluid retention and volume overload. If these side effects occur at any time in any patients during metoclopramide therapy, the drug should be discontinued.

Adverse reactions, especially those involving the nervous system, may occur after stopping the use of METOZOLV ODT.

In clinical studies, the most frequently reported adverse events (≥2% occurrence) were headache, nausea, fatigue, somnolence, and vomiting.

Complete Prescribing Information for METOZOLV ODT, including BOXED WARNING pdf

Important Safety Information about OSMOPREP

WARNINGS

There have been rare, but serious reports of acute phosphate nephropathy in patients who received oral sodium phosphate products for colon cleansing prior to colonoscopy. Some cases have resulted in permanent impairment of renal function and some patients required long–term dialysis. While some cases have occurred in patients without identifiable risk factors, patients at increased risk of acute phosphate nephropathy may include those with increased age, hypovolemia, increased bowel transit time (such as bowel obstruction), active colitis, or baseline kidney disease, and those using medicines that affect renal perfusion or function (such as diuretics, angiotensin converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs], and possibly nonsteroidal anti–inflammatory drugs [NSAIDs]).

It is important to use the dose and dosing regimen as recommended (PM/AM split dose).

OSMOPREP® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) Tablets are indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. Considerable caution should be advised before OSMOPREP is used in patients with severe renal insufficiency, congestive heart failure, ascites, unstable angina, gastric retention, ileus, severe chronic constipation, bowel perforation, toxic megacolon, gastric bypass or stapling surgery, or hypomotility syndrome. Use with caution in patients with impaired renal function, patients with a history of seizures or at higher risk of seizure, patients with higher risk of cardiac arrhythmias, known or suspected electrolyte disturbances (such as dehydration), or people taking drugs that affect electrolyte levels. Patients with electrolyte abnormalities such as hypernatremia, hyperphosphatemia, hypokalemia, or hypocalcemia should have their electrolytes corrected before treatment with OSMOPREP.

OSMOPREP is contraindicated in patients with a known allergy or hypersensitivity to sodium phosphate salts or any of its ingredients, and in patients with biopsy–proven acute phosphate nephropathy. In clinical trials, the most commonly reported adverse reactions (reporting frequency >3%) were abdominal bloating, nausea, abdominal pain, and vomiting. It is recommended that patients receiving OSMOPREP be advised to adequately hydrate before, during, and after the use of OsmoPrep.

For complete Prescribing Information for OSMOPREP including BOXED WARNING.pdf

Important Safety Information about VISICOL

WARNINGS

There have been rare, but serious reports of acute phosphate nephropathy in patients who received oral sodium phosphate products for colon cleansing prior to colonoscopy. Some cases have resulted in permanent impairment of renal function and some patients required long-term dialysis. While some cases have occurred in patients without identifiable risk factors, patients at increased risk of acute phosphate nephropathy may include those with increased age, hypovolemia, increased bowel transit time (such as bowel obstruction), active colitis, or baseline kidney disease, and those using medicines that affect renal perfusion or function (such as diuretics, angiotensin converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs], and possibly nonsteroidal anti-inflammatory drugs [NSAIDs]).

It is important to use the dose and dosing regimen as recommended (PM/AM split dose).

VISICOL® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) Tablets are indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. VISICOL is not to be used in patients with congestive heart failure, ascites, unstable angina pectoris, gastric retention, ileus or acute obstruction or pseudo-obstruction, severe chronic constipation, bowel perforation, acute colitis, toxic megacolon, or hypomotility syndrome. Use with caution in patients with impaired renal function, pre-existing electrolyte disturbances, or people taking drugs that affect electrolyte levels. VISICOL is contraindicated in patients with a known allergy or hypersensitivity to sodium phosphate salts or any of its ingredients. In clinical trials, the most commonly observed (≥1%) adverse reactions occurring with use of VISICOL were generally transient and self-limited and included nausea, vomiting, abdominal bloating, abdominal pain, dizziness and headache.

Consult with your physician to see if this product is right for you.

Complete Prescribing Information for VISICOL, including BOXED WARNING pdf

The information contained on this page is intended for US patients, healthcare professionals, and pharmacists only.

SWB 10/07

Salix Pharmaceuticals on Facebook   Salix Pharmaceuticals on Twitter